These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18382463)

  • 21. Importance of target-mediated drug disposition for small molecules.
    Smith DA; van Waterschoot RAB; Parrott NJ; Olivares-Morales A; Lavé T; Rowland M
    Drug Discov Today; 2018 Dec; 23(12):2023-2030. PubMed ID: 29928850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics: improving drug and dose selection.
    Bhathena A; Spear BB
    Curr Opin Pharmacol; 2008 Oct; 8(5):639-46. PubMed ID: 18762278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphic differences in drug metabolism and response.
    Vetticaden SJ
    Methods Find Exp Clin Pharmacol; 1988 Aug; 10(8):531-6. PubMed ID: 3067018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of drug transporters in the enterohepatic circulation.
    Stieger B; Meier PJ
    Pharmacogenomics; 2011 May; 12(5):611-31. PubMed ID: 21619426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.
    Arimany-Nardi C; Koepsell H; Pastor-Anglada M
    Pharmacogenomics J; 2015 Dec; 15(6):473-87. PubMed ID: 26526073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.
    Yu J; Ritchie TK; Mulgaonkar A; Ragueneau-Majlessi I
    Drug Metab Dispos; 2014 Dec; 42(12):1991-2001. PubMed ID: 25271211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug metabolism and liver disease: a drug-gene-environment interaction.
    Zgheib NK; Branch RA
    Drug Metab Rev; 2017 Feb; 49(1):35-55. PubMed ID: 27957864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.
    Hines RN
    Int J Pharm; 2013 Aug; 452(1-2):3-7. PubMed ID: 22766445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.
    Steere B; Baker JA; Hall SD; Guo Y
    Drug Metab Dispos; 2015 Jun; 43(6):870-83. PubMed ID: 25845826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of minipig, dog, monkey and human drug metabolism and disposition.
    Dalgaard L
    J Pharmacol Toxicol Methods; 2015; 74():80-92. PubMed ID: 25545337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.
    Alshogran OY
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1063-1073. PubMed ID: 28871815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein therapeutics: new applications for pharmacogenetics.
    Krejsa C; Rogge M; Sadee W
    Nat Rev Drug Discov; 2006 Jun; 5(6):507-21. PubMed ID: 16763661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development.
    Di L; Feng B; Goosen TC; Lai Y; Steyn SJ; Varma MV; Obach RS
    Drug Metab Dispos; 2013 Dec; 41(12):1975-93. PubMed ID: 24065860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic application in drug development and clinical trials.
    Shi MM; Bleavins MR; de la Iglesia FA
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):591-5. PubMed ID: 11259358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of stereospecific bioanalytical monitoring in drug development.
    Caldwell J
    J Chromatogr A; 1996 Jan; 719(1):3-13. PubMed ID: 8589835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 40. The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
    Perera MA
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):17-28. PubMed ID: 19968573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.